Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Discontinuation of Cholinesterase Inhibitors in Severe Alzheimer's Disease
NCT02035982Phase 3Completed
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Jul 2010
- Primary completion
- May 2014
- Modality
- Reversible Covalent Inhibitors, Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of donepezil, galantamine, rivastigmine in Alzheimer's disease (AD), sponsored by Sunnybrook Health Sciences Centre. Started Jul 2010; status: completed.
02
Drugs
donepezilgalantaminerivastigmine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02035982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02035982.